This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FARIS, P. M.
Right arrow Articles by ABELS, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FARIS, P. M.
Right arrow Articles by ABELS, R. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?
The Journal of Bone and Joint Surgery 78:62-72 (1996)
© 1996 The Journal of Bone and Joint Surgery, Inc.

The Effects of Recombinant Human Erythropoietin on Perioperative Transfusion Requirements in Patients Having a Major Orthopaedic Operation*

P. M. FARIS, M.D.{dagger}, M. A. RITTER, M.D.{dagger}, R. I. ABELS, M.D.{ddagger}, MOORESVILLE, INDIANA and AND THE AMERICAN ERYTHROPOIETIN STUDY GROUP§

Investigation performed at The Center for Hip and Knee Surgery, Mooresville

Two hundred patients who were scheduled for a major elective orthopaedic operation were enrolled in a prospective study and were randomly assigned to one of three treatment groups. Group 1 consisted of sixty patients who received recombinant human erythropoietin, 300 international units per kilogram of body weight per day; Group 2, seventy-one patients who received recombinant human erythropoietin, 100 international units per kilogram of body weight per day; and Group 3, sixty-nine patients who received a placebo. A total of fifteen doses was given subcutaneously, beginning ten days before the operation and extending through the fourth postoperative day. Patients who declined or were unable to donate autologous blood preoperatively were included in the study and were maintained on iron supplementation orally. The decision to transfuse red blood cells depended on the physician; however, physicians were encouraged not to do so if the hematocrit was more than 0.27 (27 per cent), unless the clinical symptoms warranted it. Of the 185 patients who were evaluable with regard to efficacy, significantly fewer patients received homologous red-blood-cell transfusions in Groups 1 and 2 (17 per cent [nine] and 25 per cent [sixteen], respectively) than in Group 3 (54 per cent [thirty-six]) (p < 0.001). When the patients were stratified into two groups on the basis of the pre-treatment hemoglobin level (more than 100 to 130 grams per liter or more than 130 grams per liter), we found that patients who had received a placebo and had a baseline hemoglobin level of more than 100 to 130 grams per liter were at significantly higher risk for transfusion (78 per cent [twenty-one]) than those who had received a placebo and had a baseline level of more than 130 grams per liter (36 per cent [fourteen]). For patients who had a baseline hemoglobin level of more than 100 to 130 grams per liter, the higher dose of recombinant human erythropoietin appeared somewhat more effective than the lower dose, with 14 per cent (three) of the patients in Group 1 and 39 per cent (nine) in Group 2 needing a transfusion; however, the difference was not significant (p = 0.09). For patients who had a baseline hemoglobin level of more than 130 grams per liter, the two doses of recombinant human erythropoietin produced similar results, with 14 per cent (four) of the patients in Group 1 and 11 per cent (four) in Group 2 needing a transfusion; this was in contrast to a rate of transfusion of 36 per cent (fourteen) in Group 3 (the patients who received the placebo) (p = 0.03). The recombinant human erythropoietin was generally well tolerated, although one patient, who did not have a history of hypertension, had an increase in blood pressure, from a baseline level of 142/78 millimeters of mercury (18.93/10.40 kilopascals) to a level of 220/100 millimeters of mercury (29.33/13.33 kilopascals), after ten days of treatment with the higher dose. These data suggest that recombinant human erythropoietin, administered before and after major orthopaedic operations, can minimize the need for homologous red-blood-cell transfusion.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 VASC ENDOVASCULAR SURGHome page
L. Bayam, W. F. Tait, and I. D. Macartney
Successful Repair of a Giant Abdominal Aortoiliac Aneurysm in a Jehovah's Witness
Vascular and Endovascular Surgery, November 1, 2007; 41(5): 460 - 462.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
M. A. Fischer, C. A. Morris, W. C. Winkelmayer, and J. Avorn
Nononcologic Use of Human Recombinant Erythropoietin Therapy in Hospitalized Patients
Arch Intern Med, April 23, 2007; 167(8): 840 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
D. A. Fergusson and P. Hebert
The health(y) cost of erythropoietin in orthopedic surgery/Le cout eleve de l'erythropoietine en chirurgie orthopedique
Can J Anesth, April 1, 2005; 52(4): 347 - 351.
[Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
K. Karkouti, S. A. McCluskey, L. Evans, N. Mahomed, M. Ghannam, and R. Davey
Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery: [Le traitement a l'erythropoietine reduit efficacement les transfusions de culots globulaires en chirurgie orthopedique]
Can J Anesth, April 1, 2005; 52(4): 362 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano
Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine
Arch Intern Med, February 9, 2004; 164(3): 262 - 276.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. J. Weiss
New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications
Oncologist, December 1, 2003; 8(90003): 18 - 29.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
H. P. Bezwada, D. G. Nazarian, D. H. Henry, and R. E. Booth Jr.
Preoperative Use of Recombinant Human Erythropoietin Before Total Joint Arthroplasty
J. Bone Joint Surg. Am., September 1, 2003; 85(9): 1795 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 J Am Acad Orthop SurgHome page
O. C. Johnson, C. Chebli, and A. J. Aboulafia
Epoetin Alfa
J. Am. Acad. Ortho. Surg., March 1, 2003; 11(2): 77 - 80.
[Full Text] [PDF]

Home page
 JAMAHome page
J. L. Carson
Should Patients in Intensive Care Units Receive Erythropoietin?
JAMA, December 11, 2002; 288(22): 2884 - 2886.
[Full Text] [PDF]

Home page
 J Am Acad Orthop SurgHome page
E. M. Keating and J. B. Meding
Perioperative Blood Management Practices in Elective Orthopaedic Surgery
J. Am. Acad. Ortho. Surg., November 1, 2002; 10(6): 393 - 400.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
E. S Vanderlinde, J. M Heal, and N. Blumberg
Autologous transfusion
BMJ, March 30, 2002; 324(7340): 772 - 775.
[Full Text] [PDF]

Home page
 JBJSHome page
J. A. Salido, L. A. Marin, L. A. Gomez, P. Zorrilla, and C. Martinez
Preoperative Hemoglobin Levels and the Need for Transfusion After Prosthetic Hip and Knee Surgery : Analysis of Predictive Factors
J. Bone Joint Surg. Am., February 1, 2002; 84(2): 216 - 220.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
J. E. Puzas, R. J. O'Keefe, and J. R. Lieberman
The Orthopaedic Genome: What Does the Future Hold and Are We Ready?
J. Bone Joint Surg. Am., January 1, 2002; 84(1): 133 - 141.
[Full Text]

Home page
 BloodHome page
L. T. Goodnough, B. Skikne, and C. Brugnara
Erythropoietin, iron, and erythropoiesis
Blood, August 1, 2000; 96(3): 823 - 833.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
J. M. Murkin, G. M. Haig, K. J. Beer, J. McCutchen, M. E. Comunale, R. Hall, and B. B. Ruzicka
Aprotinin Decreases Exposure to Allogeneic Blood During Primary Unilateral Total Hip Replacement
J. Bone Joint Surg. Am., May 1, 2000; 82(5): 675 - 675.
[Abstract] [Full Text]

Home page
 JBJSHome page
A. M. HATZIDAKIS, M. R. MENDLICK, T. McKILLIP, R. L. REDDY, and K. L. GARVIN
Preoperative Autologous Donation for Total Joint Arthroplasty. An Analysis of Risk Factors for Allogenic Transfusion
J. Bone Joint Surg. Am., January 1, 2000; 82(1): 89 - 100.
[Abstract] [Full Text]

Home page
 ChestHome page
G. J. Kost, S. S. Ehrmeyer, B. Chernow, J. W. Winkelman, G. P. Zaloga, R. P. Dellinger, and T. Shirey
The Laboratory-Clinical Interface: Point-of-Care Testing
Chest, April 1, 1999; 115(4): 1140 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
B. E. BIERBAUM, J. J. CALLAGHAN, J. O. GALANTE, H. E. RUBASH, R. E. TOOMS, and R. B. WELCH
An Analysis of Blood Management in Patients Having a Total Hip or Knee Arthroplasty
J. Bone Joint Surg. Am., January 1, 1999; 81(1): 2 - 10.
[Abstract] [Full Text]

Home page
 JBJSHome page
E. M. KEATING
Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Current Options and Approaches for Blood Management in Orthopaedic Surgery*{{dagger}}
J. Bone Joint Surg. Am., May 1, 1998; 80(5): 750 - 62.
[Full Text]

Home page
 Ann. Thorac. Surg.Home page
L. T. Goodnough, G. J. Despotis, and C. A. Parvin
Erythropoietin Therapy in Patients Undergoing Cardiac Operations
Ann. Thorac. Surg., December 1, 1997; 64(6): 1579 - 1580.
[Full Text]

Home page
 BloodHome page
M. Cazzola, F. Mercuriali, and C. Brugnara
Use of Recombinant Human Erythropoietin Outside the Setting of Uremia
Blood, June 15, 1997; 89(12): 4248 - 4267.
[Full Text] [PDF]

Home page
 NEJMHome page
L. T. Goodnough, T. G. Monk, and G. L. Andriole
Erythropoietin Therapy
N. Engl. J. Med., March 27, 1997; 336(13): 933 - 938.
[Full Text] [PDF]